Latest filing published 14 Mar 2022 for 泽璟制药, €32k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +49.2%Entry CN¥34.44 · Close at T+365 CN¥51.39
- +37.1%Entry CN¥36.45 · Close at T+365 CN¥49.97
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
吕彬华: trading record in brief
吕彬华 (senior executive) discloses dealings in 泽璟制药 to SSE / SZSE (CSRC). Between 11 March 2022 and 14 March 2022, the trades on record add up to 2 filings.
Every open-market trade on record is a purchase: 2 purchases worth €42k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The latest filing, published on 14 March 2022, reports an open-market purchase of €32k in 泽璟制药. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Companies and markets linked to 吕彬华
Open company profiles for insider transactions, fundamentals and analyst consensus when available.